☰

Jeremy D. Heidel, Ph.D. - Publications

Affiliations: 
2005 California Institute of Technology, Pasadena, CA 
Area:
Catalysis, Molecular Therapy
Tree Info Similar researchers PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, Tate M, Schwartz M, Zuckerman L, Lezon R, Lukas RV, Jovanovic B, McCortney K, Colman H, Chen S, ... ... Heidel J, et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Science Translational Medicine. 13. PMID 33692132 DOI: 10.1126/scitranslmed.abb3945  0.307
2014 Zuckerman JE, Gritli I, Tolcher A, Heidel JD, Lim D, Morgan R, Chmielowski B, Ribas A, Davis ME, Yen Y. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proceedings of the National Academy of Sciences of the United States of America. 111: 11449-54. PMID 25049380 DOI: 10.1073/Pnas.1411393111  0.681
2014 Primiano T, Chang B, Heidel JD. Abstract LB-103: L1CAM-targeted delivery of siRNA using elastin-like polypeptide (ELP) nanoparticles inhibits the growth of human tumors implanted in mice Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-103  0.407
2012 Heidel JD, Schluep T. Cyclodextrin-containing polymers: versatile platforms of drug delivery materials. Journal of Drug Delivery. 2012: 262731. PMID 22496980 DOI: 10.1155/2012/262731  0.435
2012 Chang B, Heidel JD, Primiano T. Abstract 1946: Silencing of EVI1 with siRNA inhibits the growth of ovarian tumor cells Cancer Research. 72: 1946-1946. DOI: 10.1158/1538-7445.Am2012-1946  0.392
2011 Heidel JD. In vivo transfection using cyclodextrin-containing polycations. Cold Spring Harbor Protocols. 2011: 1392-3. PMID 22046047 DOI: 10.1101/pdb.prot066654  0.326
2011 Heidel JD. In vitro transfection using cyclodextrin-containing polycations. Cold Spring Harbor Protocols. 2011: 1389-91. PMID 22046046 DOI: 10.1101/pdb.prot066647  0.362
2011 Heidel JD. Cyclodextrin-containing polycations for nucleic acid delivery. Cold Spring Harbor Protocols. 2011: 1319-22. PMID 22046045 DOI: 10.1101/pdb.top066639  0.374
2011 Heidel JD, Davis ME. Clinical developments in nanotechnology for cancer therapy. Pharmaceutical Research. 28: 187-99. PMID 20549313 DOI: 10.1007/S11095-010-0178-7  0.528
2010 Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 464: 1067-70. PMID 20305636 DOI: 10.1038/Nature08956  0.723
2010 Ribas A, Kalinoski L, Heidel JD, Peterkin J, Seligson DB, Zuckerman JE, Choi C, Yen Y, Davis ME, Tolcher AW. Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: Results from a first-in-class phase I clinical trial. Journal of Clinical Oncology. 28: 3022-3022. DOI: 10.1200/Jco.2010.28.15_Suppl.3022  0.707
2009 Oney S, Lam RT, Bompiani KM, Blake CM, Quick G, Heidel JD, Liu JY, Mack BC, Davis ME, Leong KW, Sullenger BA. Development of universal antidotes to control aptamer activity. Nature Medicine. 15: 1224-8. PMID 19801990 DOI: 10.1038/Nm.1990  0.503
2008 Heidel JD, Liu JYC, Zeidan RK, Liang Y, Rele SM, Davis ME. Systemic delivery of targeted, siRNA-containing nanoparticles for the treatment of solid tumors: Concept to clinic Technical Proceedings of the 2008 Nsti Nanotechnology Conference and Trade Show, Nsti-Nanotech, Nanotechnology 2008. 2: 336-337.  0.482
2007 Heidel JD, Liu JY, Yen Y, Zhou B, Heale BS, Rossi JJ, Bartlett DW, Davis ME. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2207-15. PMID 17404105 DOI: 10.1158/1078-0432.Ccr-06-2218  0.655
2007 Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proceedings of the National Academy of Sciences of the United States of America. 104: 5715-21. PMID 17379663 DOI: 10.1073/Pnas.0701458104  0.538
2006 Heidel JD. Linear cyclodextrin-containing polymers and their use as delivery agents. Expert Opinion On Drug Delivery. 3: 641-6. PMID 16948559 DOI: 10.1517/17425247.3.5.641  0.333
2006 Mishra S, Heidel JD, Webster P, Davis ME. Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes. Journal of Controlled Release : Official Journal of the Controlled Release Society. 116: 179-91. PMID 16891028 DOI: 10.1016/J.Jconrel.2006.06.018  0.669
2006 Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, Davis ME. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1606-14. PMID 16533788 DOI: 10.1158/1078-0432.Ccr-05-1566  0.651
2005 Heidel J, Mishra S, Davis ME. Molecular conjugates. Advances in Biochemical Engineering/Biotechnology. 99: 7-39. PMID 16568887 DOI: 10.1007/10_002  0.661
2005 Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Research. 65: 8984-92. PMID 16204072 DOI: 10.1158/0008-5472.Can-05-0565  0.697
2005 Rose SD, Kim DH, Amarzguioui M, Heidel JD, Collingwood MA, Davis ME, Rossi JJ, Behlke MA. Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Research. 33: 4140-56. PMID 16049023 DOI: 10.1093/Nar/Gki732  0.473
2005 Bartlett DW, Heidel JD, Davis ME. 208. Physicochemical and Biological Characterization of Cyclodextrin-Based Polycation (CDP)/siRNA Composites Designed for Systemic Delivery Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.211  0.662
2005 Heidel JD, Hu-Lieskovan S, Bartlett DW, Triche TJ, Davis ME. 70. Systemic Administration of siRNA Against EWS-FLI1 Using a Targeted, Non-Viral Formulation Inhibits Growth in a Disseminated Murine Model of Ewing's Sarcoma Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.048  0.657
2004 Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME. Lack of interferon response in animals to naked siRNAs. Nature Biotechnology. 22: 1579-82. PMID 15558046 DOI: 10.1038/Nbt1038  0.53
2004 Pun SH, Bellocq NC, Liu A, Jensen G, Machemer T, Quijano E, Schluep T, Wen S, Engler H, Heidel J, Davis ME. Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjugate Chemistry. 15: 831-40. PMID 15264871 DOI: 10.1021/Bc049891G  0.643
2004 Davis ME, Pun SH, Bellocq NC, Reineke TM, Popielarski SR, Mishra S, Heidel JD. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Current Medicinal Chemistry. 11: 179-97. PMID 14754416 DOI: 10.2174/0929867043456179  0.614
Show low-probability matches.